Tegoprazan Matches PPIs for Erosive Esophagitis Healing and Tolerability

This meta-analysis positions the potassium-competitive acid blocker tegoprazan as a mechanistically distinct, non-inferior alternative to proton pump inhibitors for erosive esophagitis, relevant to pharmacists advising on acid-suppression therapy selection.

📅 Journal publication: Aug 2026 (online Jul 27, 2026) · Last updated: Oct 7, 2026

tegoprazanpotassium-competitive acid blockerP-CABproton pump inhibitorsesomeprazolelansoprazoleerosive esophagitisGERDmeta-analysisCYP2C19acid suppression Gastroenterology / Hepatology

Background Information

Tegoprazan matches PPIs in treating erosive esophagitis effectively.

Tegoprazan offers a potential alternative for the treatment of erosive esophagitis, especially for patients who do not respond adequately to proton pump inhibitors (PPIs). Tegoprazan demonstrated non-inferior efficacy to PPIs in healing erosive esophagitis, with a risk ratio of 1.03. Tolerability was also comparable, with a rate ratio of 0.97. These findings support tegoprazan as a viable alternative to PPIs, with similar efficacy and tolerability in managing erosive esophagitis, though long-term safety data are needed. Tegoprazan is as effective and tolerable as PPIs for erosive esophagitis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Diab Y, Maalouf C, Al Hakim AJ, Chami P, Ghais A, Raad EB, Chaptini L

Citation: Diab Y, Maalouf C, Al Hakim AJ, et al. Efficacy and Tolerability of Tegoprazan Compared to Proton Pump Inhibitors in the Treatment of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JGH open : an open access journal of gastroenterology and hepatology. 2026;10(8):e70450. doi:10.1002/jgh3.70450

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →